Pharmaceutics Finalllll

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/1828

encourage image

There's no tags or description

Looks like no tags are added yet.

1829 Terms

1
New cards

why are biologics given by injection or infusion?

  1. stomach & intestines are build to breakdown proteins; stomach acid can denature a protein & digestive enzymes (proteases) cut it into small fragments, destroying its activity before it can be absorbed

  2. biologics are very large, 100-1000x heavier than small-molc so cross intestinal lining poorly even when they survive digestion

injecting drugs avoids GIT altogether


2
New cards

main route for monoclonal Ab

IV

3
New cards

bc whole dose enters circulation, IV administration can deliver ________

large doses & volumes

4
New cards

disadvantage of IV

Most IV biologics are diluted into an IV bag and infused over a period of time, so the patient must come to a clinic or infusion center, and a trained healthcare professional prepares and gives the dose

5
New cards

advantages of SC biologic administration

  • take much less time than an IV infusion

  • don’t require skilled HCP

  • pt can give at home

  • many Ab stay in body for weeks so they can be given infreq

  • convenience!!!


6
New cards

disadvantages of SC biologic administration

  • only a small volume (2mL) can be inj comfortably under the skin so drug must be packed into very conc soln

  • higher conc protein soln have higher viscosity → more likely to aggregate

  • drug is absorbed slowly from tissue into blood

  • some of drug is broken down along the way so only part of the dose reaches circulation

  • peak levels take 2 days to develop


7
New cards

Before a biologic is approved, the manufacturer must show regulators how the product behaves under ___________

realistic conditions

8
New cards

stability studies for biologics

test the product at its intended storage temperature and under stress, including after reconstitution and dilution

9
New cards

photostability testing for biologics

exposes the product to light, and shipping studies simulate the vibration, drops, and temperature changes of real transport

10
New cards

results of stability & photostability testing of biologics

results of this testing become the storage conditions, shelf life, and preparation instructions on the product label.

11
New cards

3 types of stress biologics are sensitive to in storage and handling

  1. temp

  2. mechanical stress

  3. light


12
New cards

most biologic products travel thru _______

cold chain

13
New cards

cold chain

a continuous series of refrigerated storage and transport steps designed to keep the product within the labeled temp range

14
New cards

temp excursion

any time the product falls outside its labeled range, either too warm or too cold.

  • Excursions in either direction can harm the product.


15
New cards

effect of warm excursion on biologic

speeds up unfolding & aggregation

16
New cards

mechanical stress on biologics

  • agitation (shaking, vibration, mixing)

  • shock (sudden jolts such as dropping a package)


17
New cards

what happens when a protein soln is shaken?

protein molecules collect at the boundary between the liquid and the air bubbles, where they can unfold and stick together.

18
New cards

what happens when a protein soln undergoes a sudden drop, even from a low height?

can create tiny vapor bubbles in the liquid that then collapse, a process called cavitation, which can trigger particle formation.

  • ex. pneumatic tube


19
New cards

is sunlight or indoor lighting more damaging to biologics?

sunlight

20
New cards

effect of light on biologics

can act on the protein directly, or indirectly through other ingredients in the formulation that absorb light and generate reactive species. The result can include oxidation, aggregation, loss of potency, and sometimes visible discoloration.

21
New cards

how do manufacturers address light damage in biologics?

protect products with amber glass containers and cardboard cartons, but that protection is lost once the product is taken out of its packaging

22
New cards

what kind of damage do temp, mechanical stress, and light cause to biologics?

cause the protein to unfold, fragment, or clump together (aggregate), and particles can form.

23
New cards

why do damaged biologic products work less well?

less active drug is present

24
New cards

Aggregates can also make the immune system recognize a damaged drug as foreign, leading to __________ that can reduce the drug’s effect or cause adverse reactions.

anti-drug antibodies

25
New cards

Because particles are a recognized quality concern, the United States Pharmacopeia (USP) sets limits on the number of _____________ allowed in therapeutic protein injections.

subvisible particles

26
New cards

which storage form of biologics is most vulnerable to stress?

liquid

27
New cards

how are liquid biologic products stored?

  • refrigerated within labeled range

  • protected from light in their carton

  • handled gently

  • formulation excipients such as surfactants & buffers are added to protect the protein


28
New cards

lyophilization

removes the water from a product, leaving a dry powder or “cake.” Without water, the protein is much more stable and microbes are less able to grow, so lyophilized products can be stored for long periods.

  • Sugars such as sucrose, trehalose, or mannitol are often added to protect the protein during drying and storage


29
New cards

disadvantage of lyophilized prod

must be reconstituted before given

  • adds prep step

  • prod becomes a fragile liquid again once it is dissolved, so it must be done exactly as the label describes


30
New cards

ex of frozen biologics

  • gene therapies

  • cell therapies

  • mRNA prod delivered in lipid nanoparticles


31
New cards

exposing a frozen prod to room temp during transfer can cause __________

thermal shock

32
New cards

uncontrolled freezing and thawing can damage _________________

viral particles or cells

33
New cards

main handling risks for frozen biologic storage forms

Breaks in the cold chain, thermal shock, freeze–thaw damage

34
New cards

main handling risks for lyophilized (freeze-dried powder) biologic storage forms

Becomes a fragile liquid once dissolved

35
New cards

main handling risks for liquid biologic storage

Heat, freezing, shaking, dropping, light

36
New cards

product label for biologics

  • includes detailed instructions for reconstitution, dilution, & storage after preparation

  • based on manufacturer’s testing


37
New cards

each opening of a multidose biologic container is a chance for _____________

microbial contamination


38
New cards

excipient for multidose biologics

antimicrobial preservatives

39
New cards

another name for the prepared dose (biologic)

dosing soln

40
New cards

the dosing soln can be more _____________ than the product in its original container

fragile

41
New cards

Diluting a biologic into an IV bag also dilutes the ____________ in the formulation

protective excipients

42
New cards

proteins tend to stick to (adsorb onto) surfaces such as …

plastic IV bags, tubing, filters, and the silicone oil used to lubricate syringes.

43
New cards

effect of adsorption

can lower the amount of drug the patient receives (underdosing), and adsorbed protein can unfold and seed further aggregation and particle formation

44
New cards

pt friendly devices for SC biologics

  • prefilled syringes

  • autoinjectors

  • on-body injectors that stick to the skin and deliver the dose automatically


45
New cards

why must biologic products stay in their original cartons?

to protect them from light

46
New cards

where in fridge should biologics be stored?

  • away from door

  • away from walls and other extremes


47
New cards

what should happen before a biologic dose is prepared or disp?

product should be inspected for damage or visible changes, such as particles or discoloration.

48
New cards

When doses are transported, including within the hospital, an appropriate _____________ helps protect them from drops, vibration, and temperature changes

secondary or insulated container

49
New cards

are excipients in biologics truly inactive?

no- commonly contain surfactants, sugars, and in multidose prod, preservatives

  • may cause injection-site rxns and allergic rxns


50
New cards

target of biologics

usually in plasma or on cell surface

51
New cards

monoclonal antibodies (mAbs) are often ________ specific

species

  • may not bind animal version of target


52
New cards

before using an animal model, check whether the animal…

o Expresses a version (ortholog) of the human target

o Has a target that binds the mAb with high affinity

o Has the target in similar tissues as humans

53
New cards

workarounds for finding the right species for mAbs

make a mouse version of the mAb or use transgenic animals that express the human target.

54
New cards

human and humanized proteins are __________ in animals

immunogenic

55
New cards

Anti-drug antibodies (ADAs) in animals lower exposure and can _________ toxicity.

underestimate

56
New cards

MABEL

Minimal anticipated biological effect level, based on expected target occupancy

57
New cards

the problem with using traditional NOAEL (1/10-1/100) in biologics

an animal that shows no harm may not respond like a human does

58
New cards

how is a safe first dose tested for biologics?

sentinel dosing— dose one subject & watch for a set time before anyone else

59
New cards

bioavailability of SC early clinical testing

50-70%, breakdown in tissue & lymph

60
New cards

peak plasma level after an SC biologics dose

3-7d (slow absorption)

61
New cards

half-life for SC biologics

11-30d

  • infrequent dosing


62
New cards

most mAbs trigger some ______ resp, which can…

ADA / alter PK, reduce efficacy, or cause side effects

63
New cards

resp are stronger on re-exposure, so __________ is assessed early in clinical trials

immunogenicity

64
New cards

2 licensing pathways for biologics

  1. reference product

  2. biosimilar


65
New cards

reference prod licensing pathway

“Stand-alone” BLA. Proves safety and effectiveness on its own: analytical, animal, clinical pharmacology, and clinical trials for each indication.

66
New cards

biosimilar licensing pathway for biologics

Abbreviated pathway. Proves the product is biosimilar to the reference product, so it does not repeat the reference product’s full clinical program

67
New cards

biosimilar

• A biologic that is highly similar to an FDA-approved reference product and has no clinically meaningful differences in safety, purity, and potency.

• Same route, dosage form, strength, and potential benefits and side effects as the reference product

68
New cards

are biosimilars generics?

no

69
New cards

4 parts of proving biosimilarity

  1. analytical foundation = structural & functional comparison across multiple lots

  2. clinical/pharm PK/PD = similar exposure & similar resp when a PD biomarker exists

  3. immune resp ADAs = similar type and amt of immune resp

  4. clinical study if needed = used only to resolve residual uncertainty


70
New cards

2 types of comparative analytical assays

  1. physicochemical (structural)

  2. biological (functional)


71
New cards

comparative analytical assessment focus

on quality attributes that affect clinical performance: molecular structure, bioactivity, and purity.

  • Example: post-translational modifications such as glycosylation


72
New cards

do excipients & process-related impurities have to match ref product?

no— checked for prod quality

73
New cards

are analytical or clinical studies more sensitive at detecting diff?

analytical

74
New cards

naming of biosimilars

share the reference product’s core name plus a unique 4-letter suffix with no meaning

75
New cards

purpose of biosimilar naming

pharmacovigilance (linking adverse events to the right product) and knowing which product was dispensed.

  • Use the suffix when prescribing, dispensing, record keeping, and reporting to MedWatch.


76
New cards

purple book

shows whether a biologic is a reference product, biosimilar, or interchangeable biosimilar.

77
New cards

interchangeable biosimilar

A biosimilar that a pharmacist may substitute for the reference product without the prescriber, subject to state law

78
New cards

extra standard for interchangeable biosimilars

expected to give the same clinical result in any given patient, and switching back and forth adds no more risk than staying on the reference product.

79
New cards

why is biosimilar competition limited?

  • cost to develop = $75-250 million (generic is 1-5million)

  • price drop ~30%

  • exclusivity = 12 years after reference product licensure before a biosimilar can be approved

  • price negotiation 11 yrs (7 for small molc)


80
New cards

adoption of biosimilars to pt

  1. FDA approval

  2. formulary inclusion and payor coverage which vary by insurer and plan

  3. awareness & acceptance by pt and proiders


81
New cards

what kind of pt can biosimilars be used in?

treatment naive and treatment experienced

82
New cards

Biologics follow the same stages as small molecules, but ___________ and __________ change how they are tested

species specificity / immunogenicity

83
New cards

First-in-human doses for biologics use ________ and _________ because animal data can miss human effects

MABEL / sentinel dosing

84
New cards

foundation for totality of biosimilar evidence

analytical studies

85
New cards

Interchangeable biosimilars can be substituted at the pharmacy (subject to state law) but are not ________ than other biosimilars.

better

86
New cards

production of biologics (in a living cell)

  1. The gene coding for the protein is inserted into a host cell, and the resulting cell line is frozen down as a cell bank so that every future batch starts from the same genetic point.

  2. A vial of that bank is thawed, grown up through progressively larger vessels, and transferred into the production bioreactor, where the cells are fed nutrient medium under controlled temperature, pH and dissolved oxygen while they secrete the protein into the liquid around them.

  3. The culture is then harvested, and cells and debris are removed by filtration or centrifugation, leaving a dilute solution of the product mixed with thousands of other proteins.

  4. After the culture is harvested, the product is purified. The product is captured by binding it to a chromatography column that is selective for it while unwanted proteins wash straight through.

  5. For antibodies, Protein A affinity chromatography is used, which binds the Fc region of the antibody. The bound product is then eluted with a low-pH buffer, and that acidic eluate is deliberately held at low pH for a set time, because those conditions inactivate any viruses that might have come from the cells or the raw materials.

  6. Polishing chromatography removes residual impurities, aggregates and variants, and a virus filter adds a second, physical layer of virus safety.

  7. Finally, the protein is concentrated, its buffer is exchanged for the formulation buffer, excipients are added, and the solution is sterile-filtered and filled


87
New cards

almost every step of biologic formation involves ________

stress

  • pumps & filters shear the soln

  • capture exposes the protein to acid

  • conc crowds the molc together

  • a protein that survives the bioreactor can still be damaged on its way to the vial


88
New cards

steps in biologic production chain

  1. cell banking

  2. cell culture

  3. harvest & clarification

  4. capture chromatography

  5. virus inactivation

  6. polishing & virus filtration

  7. concentration & buffer exchange

  8. formulation, filtration, & fill


89
New cards

cell banking (step 1)

A cell line carrying the gene is expanded and frozen in aliquot

  • Fixes the genetic starting point for every batch


90
New cards

cell culture (step 2)

Cells are fed in a bioreactor and secrete the protein

  • Sets glycosylation and other modifications; agitation and aeration stress the protein


91
New cards

harvest & clarification (step 3)

Cells and debris are separated from the fluid

  • Shear from pumps, centrifuges and filters


92
New cards

capture chromatography (step 4)

The product is bound, washed and then eluted at low pH

  • Acid exposure can begin to unfold the protein


93
New cards

virus inactivation (step 5)

The low-pH eluate is held for a set time

  • further acid stress


94
New cards

polishing and virus filtration (step 6)

Residual impurities, variants, aggregates and viruses are removed

  • Yield is lost, aggregates must already be low enough to filter


95
New cards

concentration & buffer exchange (step 7)

The process buffer is replaced by the formulation buffer

  • Crowding raises the risk of aggregation and high viscosity


96
New cards

formulation, filtration, and fill (step 8)

Excipients are added; the solution is sterile-filtered and filled

  • Air-liquid interfaces, pumping and container surfaces


97
New cards

Bacteria, usually Escherichia coli, grow quickly and cheaply and are a good fit for _________ proteins.

smaller, simpler

98
New cards

Mammalian cells, most often Chinese hamster ovary (CHO) cells, grow more slowly and cost far more to run, but they are used for ___________ and most other __________therapeutic proteins.

antibodies / complex

99
New cards

why are mammalian cells used for human proteins such as antibodies?

Human proteins such as antibodies carry chains of sugars attached to specific sites on the protein, a modification called glycosylation, and bacteria do not have the cellular machinery to attach human-type sugar chains

100
New cards

post-translational modification

change the cell makes to the protein after the chain has been assembled

  • most important = glycosylation

  • changes aren’t written in the gene but added by the cell’s own enzymes